The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human study of XTX301, a masked, tumor-activated interleukin-12 (IL-12), in patients with advanced solid tumors.
 
John George Knecht
Employment - Cardinal Health; CLS Health; Incyte
Leadership - Kindred Hospital Clear Lake
Stock and Other Ownership Interests - Becton Dickinson; Checkpoint Therapeutics; Fortress Biotech; Myovant Sciences; Reviva Pharmaceuticals
Honoraria - OMNI Health Media
Research Funding - Atossa Therapeutics; Cosmo Pharmaceuticals; EQRx; Phanes Therapeutics; Takeda; Xilio Therapeutics
Travel, Accommodations, Expenses - Cardinal Health
 
Anurag Gupta
Employment - Samyang Biopharm USA; Xilio Therapeutics
Stock and Other Ownership Interests - Thermo Fisher Scientific (I)
 
Meghan Duncan
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
David Crowe
Employment - Xilio Therapeutics
 
Ekta Patel
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - MustangBio; Xilio Therapeutics
Patents, Royalties, Other Intellectual Property - MustangBio; TCR2 Therapeutics
 
Jennifer O'Neil
Employment - Xilio THerapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
Patents, Royalties, Other Intellectual Property - Patents for discovery of arginase inhibitors
 
George Lee
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Katarina Luptakova
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Speakers' Bureau - BMS; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Guardant Health